Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma
Open Access
- 2 March 2009
- journal article
- Published by Springer Science and Business Media LLC in Journal of Experimental & Clinical Cancer Research
- Vol. 28 (1), 30-8
- https://doi.org/10.1186/1756-9966-28-30
Abstract
In experimental systems, interference with coagulation can affect tumor biology. We suggested that abnormal coagulation could be a negative predictor for response to immunotherapy and survival among patients with metastatic renal cell carcinoma (MRCC).Keywords
This publication has 32 references indexed in Scilit:
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinomaCancer, 2006
- Signaling of the Tissue Factor Coagulation Pathway in Angiogenesis and CancerArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Thrombin induces endocytosis of endoglin and type-II TGF-β receptor and down-regulation of TGF-β signaling in endothelial cellsBlood, 2005
- Vascular endothelial growth factor platelet counts, and prognosis in renal cancerThe Lancet, 1999
- SERUM INTERLEUKIN-6 LEVELS IN METASTATIC RENAL CELL CARCINOMA BEFORE TREATMENT WITH INTERLEUKIN-2 CORRELATES WITH PARANEOPLASTIC SYNDROMES BUT NOT PATIENT SURVIVALJournal of Urology, 1998
- Tissue factor in cancer angiogenesis and metastasisCurrent Opinion in Hematology, 1996
- Tumour necrosis factor-α, interleukin-1β and interleukin-6 in patients with renal cell carcinomaEuropean Journal of Cancer, 1994
- Platelets and cancer metastasis: A causal relationship?Cancer and Metastasis Reviews, 1992